Published in Sci Rep on October 28, 2015
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Laparoscopic surgery versus open surgery for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol (2005) 8.98
Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst (2001) 8.57
Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer (2004) 7.91
Modeling tissue morphogenesis and cancer in 3D. Cell (2007) 7.49
Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med (1997) 6.86
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res (1998) 5.86
Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci Transl Med (2014) 2.69
Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A (2001) 2.62
Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev (2003) 2.25
Hypoxia and drug resistance. Cancer Metastasis Rev (1994) 2.18
Three-dimensional in vitro tissue culture models of breast cancer-- a review. Breast Cancer Res Treat (2004) 1.88
Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today (2000) 1.86
Retracted A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer. J Natl Cancer Inst (2008) 1.84
Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res (2001) 1.83
Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist (2002) 1.78
Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology (2001) 1.75
Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther (1997) 1.71
Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther (1996) 1.66
Localization of the vegetative form of Clostridium tetani in mouse tumors following intravenous spore administration. Cancer Res (1955) 1.61
ONCOLYSIS BY CLOSTRIDIA. I. ACTIVITY OF CLOSTRIDIUM BUTYRICUM (M-55) AND OTHER NONPATHOGENIC CLOSTRIDIA AGAINST THE EHRLICH CARCINOMA. Cancer Res (1964) 1.52
Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci (2010) 1.50
3D tumour models: novel in vitro approaches to cancer studies. J Cell Commun Signal (2011) 1.47
Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Ther (2002) 1.37
A simple hanging drop cell culture protocol for generation of 3D spheroids. J Vis Exp (2011) 1.35
Clostridia in cancer therapy. Nat Rev Microbiol (2003) 1.19
Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br J Cancer (2006) 1.19
Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother (2002) 1.14
DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Res (1983) 1.14
Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system. Exp Cell Res (2012) 1.06
Improvement of Clostridium tumour targeting vectors evaluated in rat rhabdomyosarcomas. FEMS Immunol Med Microbiol (2001) 1.04
Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models. Oncol Res (2001) 1.01
Probiotic potential of lactic acid bacteria isolated from fermented dairy milks on antiproliferation of colon cancer cells. Biotechnol Lett (2008) 0.96
The use of clostridial spores for cancer treatment. J Appl Microbiol (2006) 0.95
Evaluation of Clostridium novyi-NT spores in dogs with naturally occurring tumors. Am J Vet Res (2012) 0.95
Clostridium spores as anti-tumour agents. Trends Microbiol (2006) 0.94
Immunomodulatory and antitumor effects in vivo by the cytoplasmic fraction of Lactobacillus casei and Bifidobacterium longum. J Vet Sci (2004) 0.91
3D versus 2D cell culture implications for electron microscopy. Methods Cell Biol (2010) 0.90
Anti-proliferative effects of Bifidobacterium adolescentis SPM0212 extract on human colon cancer cell lines. BMC Cancer (2008) 0.89
Effects of medium composition on the morphology and function of rat hepatocytes cultured as spheroids and monolayers. In Vitro Cell Dev Biol Anim (2002) 0.86
Avitalized bacteria mediate tumor growth control via activation of innate immunity. Cell Immunol (2011) 0.86
ONCOLYSIS BY CLOSTRIDIA. IV. EFFECT OF NONPATHOGENIC CLOSTRIDIAL SPORES IN NORMAL AND PATHOLOGICAL TISSUES. Cancer Res (1964) 0.86
Approaches to defining the mechanism of enhancement by Fluosol-DA 20% with carbogen of melphalan antitumor activity. Cancer Res (1987) 0.82
Application of a fluorescence resonance energy transfer (FRET)-based biosensor for detection of drug-induced apoptosis in a 3D breast tumor model. Biotechnol Bioeng (2015) 0.82
Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents. Cancer Res (1984) 0.79
Inhibition of the genotoxicity of bleomycin by superoxide dismutase. Mutat Res (1984) 0.79
Elucidating the in vivo targets of bacterial toxins. Future Microbiol (2007) 0.79
Long-term outcomes following resection of retroperitoneal recurrence of colorectal cancer. Eur J Surg Oncol (2013) 0.77
[Tumor hyperthermia using high frequency for increase of oncolysis by clostridium butyricum (M 55)]. Strahlentherapie (1976) 0.77
Suppressive effect of Clostridium perfringens-produced heat-stable substance(s) on proliferation of human colon adenocarcinoma HT29 cells in culture. Cancer Lett (2005) 0.77